Meeting
2023 ASCO Annual Meeting
Final results of pilot trial to evaluate anti-PD1 and 8 Gy in 1 fx for relapsed refractory multiple myeloma.
Authors
Mohammad Khurram Khan
Emory University, Atlanta, GA
Mohammad Khurram Khan , Tahseen Nasti , Troy Kleber , Josh Qian , Jeffrey M. Switchenko , Clayton B Hess , Jonathan L. Kaufman , Ajay K. Nooka , Madhav V. Dhodapkar , Dabedochukwu Obiekwe , Sagar Lonial , Rafi Ahmed
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT03267888
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 8017)
DOI
10.1200/JCO.2023.41.16_suppl.8017
Abstract #
8017
Poster Bd #
9
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Prolonged 14-day continuous infusion of high-dose ifosfamide (14IFO) for relapsed/refractory high-grade osteosarcoma (R/R HOS): A retrospective multicenter cohort study.
First Author: Elisa Tirtei
Poster
2023 ASCO Annual Meeting
A single-arm, multi-institutional, phase 2 study of a pembrolizumab-based organ preservation strategy for locally advanced larynx cancers: SMART-KEY (LACOG 0720) trial.
First Author: Thiago Bueno Oliveira Sr.
Poster
2021 ASCO Annual Meeting
High-dose lenalidomide and melphalan as conditioning for autologous stem cell transplantation in relapsed or refractory multiple myeloma.
First Author: Adriana C. Rossi
Poster
2018 ASCO Annual Meeting
Off treatment survival (OTS) in patients (pts) with advanced melanoma after anti-PD1 therapy.
First Author: Shelly Ann Christiansen